4.8mg Zenrelia for Dogs
Zenrelia 4.8mg is a once-daily, tablet formulated for dogs aged twelve months and older to manage the itch and inflammation linked to allergic and atopic dermatitis. The active ingredient, ilunocitinib, acts as a non-selective Janus kinase (JAK) inhibitor. It works by interrupting key inflammatory signalling pathways that trigger itch sensations and skin irritation. Zenrelia is not a corticosteroid or antihistamine, but instead targets the underlying immune-mediated mechanisms that fuel pruritus and lesion formation.
Since ilunocitinib is rapidly absorbed and has a short half-life, the tablet begins to provide relief swiftly following administration and clears from the dog’s system within about 24 hours if treatment is paused. This pharmacokinetic profile offers dosing flexibility, permitting treatment to be initiated or stopped as needed, for instance, during diagnostic food trials without lingering drug accumulation.
4.8mg Zenrelia is designed for convenience and compliance. It can be administered with or without food and requires no loading dose or tapering phase. The scoring on the tablets in multiple strengths enables precise dosing from as low as approximately 0.6 mg per kilogram up to 0.8 mg per kilogram (0.27–0.36 mg per pound). This makes Zenrelia adaptable for dogs of different sizes and weight classes.
In clinical trials involving several hundred dogs with allergic or atopic dermatitis, Zenrelia demonstrated rapid reduction in itch scores and skin lesion severity, with outcomes comparable to or exceeding those of existing JAK inhibitors. Visual and numerical assessments showed notable improvements in both itching and inflammation within weeks of treatment commencement. The repeat-daily dosing maintained this effect over the longer term, supporting skin health and owner satisfaction.
VETERINARY PRESCRIPTION REQUIRED